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Abstract 
Background: Determining the anatomic compartments that contribute to plasma HIV-1 is critical to understand-
ing the sources of residual viremia during combination antiretroviral therapy (ART). We analyzed viral DNA and RNA 
populations in the plasma and tissues from macaques infected with SIV containing HIV-1 RT (RT-SHIV) to identify 
possible sources of persistent viremia and to investigate the effect of ART on viral replication in tissues. Tissues were 
collected at necropsy from four pigtailed macaques infected for 30 weeks with a diverse population of RT-SHIV. Two 
animals (6760 and 8232) were untreated and two animals (8030 and 8272) were treated with efavirenz, tenofovir, and 
emtricitabine for 20 weeks.
Results: A total of 1800 single-genome RT-SHIV pol and env DNA and RNA sequences were analyzed from the 
plasma, PBMCs, axillary and mesenteric lymph nodes, spleen, thymus, small intestine, bone marrow, lung, and brain. 
Analyses of intracellular DNA and RNA populations revealed that the majority of proviruses in tissues from untreated 
animal 8232 were not expressed, whereas a greater proportion of proviruses in tissues were expressed from 6760. Few 
intracellular RNA sequences were detected in treated animals and most contained inactivating mutations, such as 
frame shifts or large deletions. Phylogenetics showed that RT-SHIV DNA populations in tissues were not different from 
virus in contemporary plasma samples in the treated or untreated animals, demonstrating a lack of anatomic com-
partmentalization and suggesting that plasma viremia is derived from multiple tissue sources. No sequence diver-
gence was detected in the plasma or between tissues in the treated animals after 20 weeks of ART indicating a lack of 
ongoing replication in tissues during treatment.
Conclusions: Virus populations in plasma and tissues did not differ significantly in either treated or untreated 
macaques, suggesting frequent exchange of virus or infected cells between tissues and plasma, consistent with 
non-compartmentalized and widely disseminated infection. There was no genetic evidence of ongoing replication in 
tissues during suppressive ART.
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Background
Identifying the sources of persistent plasma HIV-1 dur-
ing treatment with antiretroviral therapy (ART) is criti-
cal for designing strategies to target virus producing 
cells for elimination. Previous studies have attempted to 
determine whether persistent viremia during successful 
combination ART results from incomplete suppression 
of virus replication [1–9] or if it is produced by long-lived 
and/or proliferating infected cells [2, 9–18]. Our recent 
study on the genetics of persistent viremia during ART 
[18] showed that the plasma viral population after long-
term ART consists of the same variants that were pre-
sent prior to initiating ART, indicated that it originated 
from cells, or the descendants of cells, that were infected 
prior to therapy. Furthermore, investigations by Bailey 
et al. and Kearney et al. on the genetics of plasma viremia 
determined by single-genome sequencing revealed popu-
lations of identical viral sequences present during ART 
[11, 18]. These findings together imply that persistent 
viremia during ART may be the result of virus release 
from long-lived, proliferating cells and not from on-
going, virus replication. Direct evidence now exists that 
supports the idea that persistent viremia is maintained 
by the expression of virus from proliferating blood cells 
[19]. This study showed clear evidence of proliferation of 
infected CD4+ T-cells collected from patients at various 
times before and during therapy. Furthermore, Maldarelli 
et al. identified a population of proliferating CD4+ cells 
that carried a viral variant that was also predominant 
in the plasma of a patient on ART [19]. These findings 
provide the strongest evidence to date that persistent 
viremia during ART can arise from expression of HIV-1 
from expanded CD4+ cell populations that were infected 
prior to initiating therapy. A subset of such proliferating 
cells is likely the reservoir for viral rebound when ART is 
interrupted and, therefore, must be eliminated to control 
HIV-1 infection off ART.
The magnitude and the distribution of the HIV reser-
voir that contributes to viral rebound off ART are incom-
pletely defined. One study (Simonetti et  al. CROI 2015) 
showed that identical HIV-1 sequences found in the 
plasma of an individual being treated with ART origi-
nated from cells in the blood, gut, and lymph nodes that 
were clonally expanded from a single infected progenitor. 
These findings suggest that infected, proliferating cells 
are widely distributed without evidence of compartmen-
talization, and that persistent viremia during ART may 
be derived from multiple tissue sources. By contrast, 
other studies aimed at profiling HIV-1 genetics have con-
cluded that the virus is sometimes compartmentalized 
across tissues [20–39]. These conflicting results may be 
explained in part by a study by Bull et al. who showed that 
the appearance of compartmentalization, in at least some 
cases, is due to sampling error and/or over-representa-
tion of identical viral variants resulting from cell prolifer-
ation and not from unique HIV-1 populations existing in 
different tissues [40]. These findings suggest that infected 
cells are well distributed across tissues (the brain and 
genital secretions may be exceptions [41]) and that local 
expansion of infected cells may influence the frequency 
of viral variants detected within tissues, giving the false 
appearance of compartmentalization. A widely distrib-
uted and well mixed model of HIV-1 populations would 
predict that as new variants emerge in tissues, they would 
be rapidly disseminated through blood to other compart-
ments, as opposed to local compartmentalization of new 
variants through ongoing replication. If the well mixed 
model is confirmed, it would have important implica-
tions including: (1) plasma virus population would mir-
ror populations in tissues and, as such, could be used to 
monitor diversity and evolution in tissues, (2) variants 
arising from ongoing replication in sanctuary tissues sites 
would be rapidly disseminated to other tissues and read-
ily detectable in the blood, and (3) expanded clones that 
may be an important reservoir for HIV would be spread 
throughout tissues.
Additional studies are needed to determine if HIV-1 
is well distributed or is compartmentalized across tis-
sues. These studies are challenging to perform in humans 
because of the difficulty in obtaining relevant human 
samples for testing. Animal models are an appropriate 
substitute for such investigations as they enable exten-
sive sampling, including collection at scheduled necropsy, 
allowing for expansive and detailed analyses of the viral 
populations in blood and tissues. Animal models also 
eliminate the complications of inter-host viral diversity 
and incomplete treatment adherence, which are com-
mon issues in human studies. Previous studies of infected 
macaques have shown that intracellular viral RNA and 
viral DNA are present in many tissues [42, 43] and that 
plasma virus is derived from multiple tissue sources such 
as the gut [44, 45] or from the lymph nodes [46]. To inves-
tigate both the anatomic sources of persistent plasma virus 
during ART, the nature of proliferating cells (marked by 
expanding viral variants), and the possibility of on-going 
viral replication in the tissues during ART, we character-
ized the genetics of viral variants across anatomic sites in 
untreated and ART-treated pigtailed macaques infected 
with a strain of SIVmne containing HIV-1 RT (RT-SHIVmne) 
[43, 47, 48]. Infection with RT-SHIVmne has previously 
been shown to result in pre-therapy RNA levels that are 
similar to HIV-1 infection in humans, to display dynam-
ics of viral decay on ART similar to that in humans, and to 
achieve sustained levels of suppression on ART to <30 cop-
ies/ml [47, 48]. Additionally, RT-SHIVmne animal models 
have been shown to be appropriate systems to investigate 
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the viral genetics of persistent viremia [49]. In the cur-
rent study, we used the RT-SHIVmne macaque model to 
investigate the sources of plasma viremia, the distribu-
tion of identical sequences in tissues, and the possibility 
of on-going replication in tissues during ART by analyz-
ing single-genome sequences obtained from 11 different 
anatomic sites in four pigtailed macaques infected with a 
diverse population of RT-SHIVmne. We hypothesized that 
infected cells would be well dispersed across tissues, mak-
ing the viral populations indistinguishable from plasma 
virus and implying multiple anatomic origins of persistent 
viremia and the lack of on-going replication in tissues [18].
Results and discussion
Viral DNA and RNA levels in plasma and tissues 
from RT‑SHIV‑infected macaques
We used a subset of samples from four macaques 
reported in a previous study to have persistent levels 
of infected cells and RT-SHIVmne expression (hereafter 
denoted RT-SHIV). As described previously, plasma sam-
ples were collected weekly from the 4 pigtailed macaques 
after inoculation with RT-SHIV and tissue samples were 
obtained at necropsy 30  weeks post-infection [43]. Two 
of the animals (6760 and 8232) were left untreated, and 
two (8272 and 8030) were treated daily with efavirenz, 
tenofovir, and emtricitabine, beginning 10  weeks post-
infection, and continued until sacrifice [43]. As published 
by Kline et  al. plasma viremia was measured weekly or 
biweekly throughout the original study and showed a 
thousand-fold difference in set point between the two 
untreated animals (6760–105 and 8232–102) as well as 
sustained suppression of viremia <30 copies/mL after 
5–10  weeks of ART in both treated animals. DNA and 
RNA were isolated from necropsy tissues, quantified as 
previously reported [43] and as described briefly in the 
methods, and were used for single-genome sequencing in 
this study (Table 1, Additional file 1: Figure S1). By ana-
lyzing data from Kline et  al. we found that, despite the 
thousand-fold difference in plasma RNA levels at the 
set point in the two untreated animals, the mean differ-
ence between levels of RT-SHIV DNA in their tissues 
was less than 2-fold. This finding suggests that the higher 
levels of viremia in untreated animal 6760 compared to 
untreated animal 8232 is more likely due to higher lev-
els of expression of virus from infected cells rather than 
to a higher frequency of infected cells. This conclusion 
was confirmed by measuring levels of RT-SHIV RNA 
in the tissues in these animals, which showed a ratio of 
108:1 (RNA:DNA) in animal 6760 and 8:1 in animal 
8232. In the two ART-treated animals, RT-SHIV-infected 
cells were readily detectable but, the levels of viral RNA 
expression in tissues collected after 30  weeks of treat-
ment were rarely above the limit of the assay detection, 
indicating that the infected cells that persisted during 
ART expressed few viral transcripts (Table 1).
RT‑SHIV diversity of the challenge virus and diversity 
and divergence in animals 1 week post‑infection vs. 
30 weeks post‑infection
Single-genome sequencing (SGS) of the RT-SHIV RT cod-
ing region was performed on the virus challenge stock 
and on plasma collected from each animal 1 week post-
infection. The viral populations in each sample were ana-
lyzed using neighbor-joining trees which are capable of 
reliably identifying identical variants, a key part our analy-
ses throughout the study (Fig.  1). The RT-SHIV popula-
tion in the challenge stock was heterogeneous, likely due 
to its history of serial passage in cell culture [43], and 
similar sets of variants successfully established infection 
in all four macaques (Fig.  1). Although the populations 
in the plasma and the challenge stock were diverse, they 
did include several dominant variants that could be used 
to track the seeding and spread of specific variants across 
the tissues (Fig. 1, numbered 1–5). The similarities of the 
viral population after inoculation in all four animals imply 
that differences in viral set point were not related to the 
diversity of the variants that established infection. The 
heterogeneity early in infection in these animals resulted 
in populations that more closely resembled chronic HIV-1 
infection in humans than homogeneous acute infections.
In addition to comparing the early plasma diversity to 
the RT-SHIV challenge virus, we also compared the viral 
genetic diversity in the plasma at week 1 to the plasma 
diversity at week 30 in each animal to look for evidence 
of viral evolution over time by using phylogenetics and 
a test for panmixia (Fig. 2). The panmixia test is used to 
determine the probability that two subpopulations are 
derived from the same, well-mixed population. Due to 
the large numbers of comparisons between sequences 
and the possibility of sampling error, pairs of popula-
tions with panmixia probabilities of <10−3 are considered 
significantly different [18, 49, 50]. Plasma populations 
obtained at week 30 were found to be significantly dif-
ferent from week 1 populations in the untreated animals 
(p = 10−4 in animal 6760 and p < 10−10 in 8232), but not 
in the animals treated with ART (p =  0.08 in 8030 and 
p = 0.4 in 8272) (Fig. 2). We also normalized the data to 
account for differences in sampling between the treated 
and untreated animals to be sure that the panmixia test 
was not influenced by undersampling in the treated ani-
mals and found little difference in the panmixia results 
(p = 0.0005 in animal 6760 and p = 0.0003 in 8232). We 
accomplished this by generating a script to randomly 
select 20 sequences from week 1 in the untreated ani-
mals (to match the number of sequences in the treated 
animals at week 1) and to randomly select 7 sequences 
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from week 30 in the untreated animals (to match the 
number of sequences in the treated animals at week 30), 
which were then tested for panmixia. This finding implies 
that significant levels of virus evolution due to replication 
occurred in the untreated animals over 29 weeks but that 
there was little or no RT-SHIV replication in the blood 
of the animals treated with ART, consistent with previ-
ous HIV-1 studies in humans [18]. The analyses showed 
that the change in panmixia in untreated animal 6760 
was associated with increasing viral population diversity 
(0.3–0.5 %), corresponding to the emergence of new vari-
ants with longer branches on the trees than the variants 
present at week 1 (Fig. 2a). Only clones 4 and 5 were still 
detectable after 30  weeks of infection in animal 6760. 
By contrast, analysis of samples from untreated 8232 
revealed evolution by evidence of a genetic bottleneck in 
this animal that occurred between week 1 and week 30, 
selecting especially for clone 4 and resulting in a decrease 
in viral diversity (0.4–0.2  %) (Fig.  2b). These data show 
that viral evolution in this model can result from the 
emergence of new variants, as in animal 6760, or from 
the selection of existing variants, as in animal 8232. 
Fewer sequences were obtained from the animals on sup-
pressive ART but the sequences obtained were not phylo-
genetically different from the population present prior to 
ART initiation (Fig. 2c, d) indicating that no viral evolu-
tion could be detected in blood samples. Two additional 
clonal variants detected in the phylogenetic analyses in 
Fig. 2 that are also present in later analyses were labeled 6 
and 7 for reference across figures and text.
Fig. 1 Phylogenetic relationships between single-genome 
sequences obtained from the challenge virus stock and from the 
plasma collected at one week post-infection from each animal. G to 
A hypermutants are marked by crosses. Numbers refer to clusters of 
sequences observed more than once here and in subsequent figures. 
Symbols shown in boxes indicate identical sequences that are present 
on the tree at the location indicated by the pointer
a b
dc
Fig. 2 Phylogenetic and panmixia relationships between single-
genome plasma sequences obtained one week and 30 weeks post-
infection from each animal. Neighbor-joining trees were prepared 
using consensus B as an out group (bottom, unlabeled branch) for the 
untreated (a, b) and treated (c, d) animals. The p values shown next 
to each animal identifier denote the probability that the virus popula-
tions sampled at one week and 30 weeks after infection are not differ-
ent (panmixia). Numbers refer to clusters of sequences observed more 
than once here and in previous and subsequent figures. Symbols 
shown in boxes indicate identical sequences that are present on the 
tree at the location indicated by the pointer. G to A hypermutants are 
marked by crosses. Asterisks indicate bootstrap values >80
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Analyses of RT‑SHIV proviral populations in multiple 
tissues of untreated animals
The genetics of the RT-SHIV DNA populations were 
compared across tissues after 30  weeks of infection in 
the untreated animals and were compared to the plasma 
virus at week 1 and week 30 to investigate the spread 
and persistence of viral variants within and between tis-
sues and to investigate the anatomic sources of plasma 
viremia. The tissues included peripheral blood mono-
nuclear cells (PBMCs), axillary and mesenteric lymph 
nodes (LN), small intestine (ileum, duodenum, jejunum), 
lung, thymus, spleen, bone marrow, and brain from one 
untreated animal (6760). Table  1 shows the number of 
DNA single-genome sequences obtained from each tis-
sue. DNA populations were compared using (1) aver-
age pairwise distance (APD) calculations to measure the 
genetic diversity within each population (Table  2), (2) 
the test for panmixia to measure divergence between the 
tissue populations and the plasma virus at week 1 and 
week 30 (Table 2; Fig. 3), and (3) neighbor-joining analy-
ses to investigate the clustering of sequences within and 
between anatomic sites (Fig. 3a, b).
A wide range of proviral diversity was found across the 
tissues (0.09–0.85 %) (Table 2), suggesting that there may 
be differences among tissue populations. Different tissues 
or anatomical compartments are likely to exert different 
selective pressures on viral populations, which could have 
dramatic effects on viral diversity. Proviral diversities in 
the tissues of animal 6760 increased relative to the week 
1 plasma virus, while tissue diversities in animal 8232 
decreased, findings consistent with those in the plasma of 
the same animals. These changes reflect the emergence of 
new variants in 6760 and the genetic bottleneck in 8232 
and imply that the viral populations in the tissues and 
plasma virus are well mixed.
Further investigations of sequences from the untreated 
macaques using the panmixia test showed that although 
there was a wide range of diversity across the tissues; 
divergence measured from the plasma virus at the same 
time point (week 30) was significantly different for only 
two tissues sites: spleen in 6760 and mesenteric lymph 
node in 8232 (Table 2; Fig. 3). This finding indicates that 
the same viral variants are present in plasma and across 
most tissues after 30 weeks of infection and that the wide 
range in intra-tissue diversity must be due to either sam-
pling error or to different frequencies of the same vari-
ants within each tissue compartment.
Neighbor-joining trees confirmed that the vast major-
ity of proviral pol sequences obtained from different ana-
tomical compartments were not different from each other 
or from the plasma virus at the same time point (Fig. 3a, 
b). Importantly, these data demonstrate that the evolu-
tion that occurred between week 1 and week 30 in these 
animals is reflected across the tissues analyzed, suggest-
ing that these tissue compartments are more likely con-
nected rather than compartmentalized. Single-genome 
Table 2 pol population diversity and divergence,between plasma (week 30) and tissues at necropsy (week 30/31)
– Too few sequences to analyze (<7 sequences)
* p value (10−3  was used as the criterion for significance due to the numbers of multiple comparisons. Significant differences indicated by bold)
a Probability of panmixia of sequences in each tissue compared to an equal number of randomly selected unique sequences in the plasma
Tissue Untreated Treated
6760 8232 8272 8030
APD (%) Panmixiaa  
(19 sequences)
APD (%) Panmixiaa  
(17 sequences)
APD (%) Panmixiaa  
(7 sequences)
APD (%) Panmixiaa  
(12 sequences)
Challenge virus 0.23 <10−6* 0.23 <10−6* 0.23 0.59 0.23 0.04
Plasma week 1 0.28 10−4* 0.36 <10−6* 0.3 0.4 0.19 0.08
Plasma week 30 0.5 NA 0.19 NA 0.17 NA 0.35 NA
PBMC 0.85 0.13 0.41 0.07 0.39 0.28 0.26 0.63
Duodenum 0.3 0.002 0.09 0.06 0.32 0.05 0.14 –
Jejunum 0.43 0.07 0.4 0.48 0.41 0.37 0.37 0.3
Ileum 0.59 0.08 0.17 0.53 1.19 – – –
Lung 0.82 0.27 0.25 0.06 0.85 0.39 – –
Thymus 0.46 0.001 – – – – – –
Bone marrow 0.47 0.35 0.23 0.24 0.65 0.23 0.33 0.85
Spleen 0.61 0.0004* 0.21 0.72 0.28 0.33 0.19 0.521
Axillary LN 0.5 0.008 0.23 0.002 0.55 0.22 – –
Mesenteric LN 0.49 0.45 0.39 0.00090* 0.64 0.02 0.24 0.64
Mean APD 0.55 0.26 0.59 0.26
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a b
Fig. 3 Phylogenetic relationships between single-genome proviral sequences obtained from various anatomical compartments 30 weeks post-
infection from the untreated animals a 6760 and b 8232. The panmixia probabilities comparing virus populations in the tissues (open colored circles) 
with sequences in the plasma (solid black circles) are shown next to each tissue in the key. G to A hypermutants are marked by crosses. Numbers 
refer to clusters of sequences observed more than once here and in previous and subsequent figures. Symbols shown in boxes indicate identical 
sequences that are present on the tree at the location indicated by the pointer
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env sequences were also obtained from one animal (6760) 
with the same finding of sequence intermingling across 
tissues as was found for RT (Additional file 2: Figure S2). 
Phylogenetic analyses also showed that the variable diver-
gences in two tissues (spleen in 6760 and thymus in 8232) 
were due to differing frequencies of identical sequences 
between tissues and plasma; specifically, differences in 
frequencies of clone 4. Clone 4 was under-represented in 
the spleen in animal 6760 and in the mesenteric LN in 
animal 8232 resulting in statistically “divergent” popula-
tions. This observation was confirmed by collapsing all 
identical sequences to single variants, resulting in the 
loss of significant divergence by panmixia. The different 
frequencies of these variants across some tissues could 
be due to sampling error, differential seeding of variants 
from the challenge virus stock, or from clonal expansion 
of infected cells. Of note, clones 1, 3, 4, and 5 persisted 
in the tissues in animal 8232 after 30 weeks of infection 
whereas these variants (except 4) disappeared from the 
plasma due to a genetic bottleneck that occurred with the 
section of clone 4 (only reaching significance in the mes-
enteric LN). Clones 1, 4, and 5 remained detectable in at 
least some of the tissues of animal 6760 (Fig.  3a), while 
only clones 4 and 5 were present in the plasma (reach-
ing significance in the spleen). Only 5 sequences were 
recovered from the brain tissue samples. All 5 sequences 
were obtained from the cerebrum of the untreated ani-
mal, 6760 with the highest viral set point. Three of the 5 
variants matched those found in other tissues while two 
were unique but closely related (Fig. 3a). These findings 
show a lack of significant compartmentalization of virus 
in the brain of this pigtailed macaque, consistent with 
that observed across other tissues (albeit with limited 
sampling in this case). This observation is distinct from 
that in humans where clear evidence for HIV-1 compart-
mentalization has been shown in cerebral spinal fluid 
compared to blood in some individuals [29]. In total, 
the DNA populations in the tissues differed significantly 
only by the variable frequencies of identical sequences, 
indicating that viral variants and/or infected cells are 
well mixed across tissues. Plasma virus contained sub-
populations that were not different from the proviral 
populations in the tissues examined. This finding strongly 
suggests that viremia is most likely derived from infected 
cell populations that have spread across most, if not all, 
tissues in the body.
Analyses of RT‑SHIV intracellular RNA populations 
in tissues of untreated animals
To characterize the diversity and divergence of RT-SHIV 
variants expressed in different tissues and to further 
investigate the sources of plasma viremia, we obtained 
intracellular viral RNA sequences and compared these 
populations to those obtained from plasma (Fig.  4) 
and to the proviral populations from the same tissues 
(Figs. 5, 6). Table 1 shows the number of RNA sequences 
obtained from each tissue. Neighbor-joining trees of 
intracellular RNA sequences obtained across tissues 
from the untreated animals are shown in Fig. 4. Similar 
to the viral DNA populations, intracellular RNA vari-
ants in the untreated animals intermingled between tis-
sue and plasma sequences and showed no divergence by 
panmixia (Table 2), revealing a lack of anatomic compart-
mentalization and a lack of isolated, local evolution or 
expression in these animals (Fig.  4). These data support 
our conclusions from the proviral sequence analyses that 
the infected cells are well mixed across anatomic com-
partments and that plasma virus could be derived from 
multiple anatomic sites. We also found that the expressed 
populations contained clusters of identical sequences 
(Fig.  4), suggesting either that multiple cells carrying 
identical variants are expressing viral RNA (likely the 
case for previously identified clones such as clone 4) or 
that a single cell per tissue is undergoing high levels of 
viral expression in comparison to other infected cells 
(possibly the case for identical sequences that were not 
found to be clonal in the DNA, such as those labeled 7, 9, 
and 10 in Fig. 4).
Direct phylogenetic and panmixia comparisons of 
intracellular RNA and proviral DNA populations from 
untreated animals 6760 and 8232, including expres-
sion from cells carrying identical sequences, are shown 
in Figs. 5 and 6. Clonal variants were expressed at vary-
ing levels in different tissues, ranging from undetectable 
to high levels of expression. Phylogenetic relationships 
between intracellular RNA and DNA single-genome 
sequences obtained from the same anatomical compart-
ments after 30 weeks of infection from untreated animal 
6760 showed no structural differences (Fig. 5), indicating 
that the infected cells expressing viral RNA are diverse, 
likely contributing to the high level of plasma viremia in 
this animal. Panmixia p values are shown where more 
than 7 sequences were obtained for both RNA and DNA 
and, with one exception, show a lack of significant prob-
ability that the RNA population is different from the 
DNA population (Fig.  5). This finding suggests that, in 
the absence of ART, a large fraction of the infected cells 
across all tissues appear to be expressing viral RNAs. By 
contrast, phylogenetic analyses of intracellular RNA and 
DNA from the same anatomical compartments after 
30  weeks of infection in untreated animal 8232 with a 
low viral set point (1000-fold lower than in animal 6760) 
showed a significant difference in panmixia in some of 
tissues analyzed (Fig. 6). The difference was primarily due 
to dominance of viral expression from clonal proviruses 
4 and 8, shown in the trees as RNA sequences matching 
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Fig. 4 Phylogenetic relationships between intracellular RNA single-genome sequences obtained from different anatomical compartments 
30 weeks post-infection from untreated animals 6760 and 8232. Numbers refer to clusters of sequences observed more than once here and in 
previous and subsequent figures. Symbols shown in boxes indicate identical sequences that are present on the tree at the location indicated by the 
pointer
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Fig. 5 Phylogenetic relationships between intracellular RNA and DNA single-genome sequences obtained from the same anatomical compart-
ments 30 weeks post-infection from untreated animal 6760. p values for panmixia are shown where more than 7 sequences were obtained for both 
RNA and DNA. Numbers refer to clusters of sequences observed more than once here and in previous and subsequent figures. Symbols shown in 
boxes indicate identical sequences that are present on the tree at the location indicated by the pointer
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the DNA variants and identified with their clonal refer-
ence numbers. This finding suggests that a smaller pro-
portion of infected cells were expressing RT-SHIV RNA 
in this animal compared to animal 6760, consistent with 
the lower level of plasma viremia in animal 8232. Analy-
ses of intracellular RNA populations revealed that the 
majority of proviruses in tissues from 8232 were not 
likely expressed, whereas tissues from 6760 had a greater 
a b c
ed
Fig. 6 Phylogenetic relationships between intracellular RNA and DNA single-genome sequences obtained from the same anatomical compart-
ments 30 weeks post-infection from untreated animal 8232. p values for panmixia are shown where more than 7 sequences were obtained for both 
RNA and DNA. Numbers refer to clusters of sequences observed more than once here and in previous and subsequent figures. Symbols shown in 
boxes indicate identical sequences that are present on the tree at the location indicated by the pointer
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proportion of proviruses being expressed. These data 
suggested two important findings: (1) compartmentali-
zation of proviral populations in the tissues compared to 
viral populations in the blood was only very rarely statis-
tically significant, and (2) when rare compartmentalized 
proviral populations did occur, the variants that were 
expressed were not different from the virus population in 
plasma. These findings are important because they imply 
that exchange of virus and/or infected cells between the 
blood and the tissues may be frequent and that viral evo-
lution may not occur in isolation in the tissues in the 
animal model studied. Although local viral spread may 
occur, it appears to be in tandem with the mixing of vari-
ants between all the tissues and the blood.
Analyses of RT‑SHIV proviral populations in multiple 
tissues of animals treated with ART
The genetics of the RT-SHIV DNA populations were 
compared across tissues and to the plasma virus at week 
1 and week 30 in the two macaques treated for 20 weeks 
with combination ART to investigate the spread and per-
sistence of viral variants within and between tissues and 
to investigate the anatomic sources of persistent viremia 
during ART. Table  1 shows the number of DNA single-
genome sequences obtained from each tissue in the two 
treated macaques, 8030 and 8272. DNA populations 
were compared using (1) APD calculations to measure 
the genetic diversity within each population (Table  2), 
(2) the test for panmixia to measure divergence between 
the tissue populations and between tissues and plasma 
(Table 2), and (3) neighbor-joining analyses to investigate 
the clustering of sequences within and between anatomic 
sites and with plasma virus (Fig. 7a, b).
As in the untreated animals, a wide range of proviral 
diversity was found across the tissues (0.14–1.19 %) with 
no overall reduction after 20 weeks of therapy (Table 2). 
This finding suggests that there may be differences 
among the populations between tissues (maybe due to 
different frequencies of G to A hypermutants) and that 
this distribution is not affected by short-term combina-
tion ART. A lack of change in viral diversity with short-
term therapy is consistent with our previous observation 
of plasma virus in HIV-infected humans on ART [18] 
and in RT-SHIV-infected macaques on suppressive ART 
[18]. Further investigation of sequences from the treated 
macaques using the panmixia test showed that, although 
there was a wide range of diversities across the tissues, 
the populations were not significantly divergent from 
each other or from the plasma virus at the same time 
point (Table 2; Fig. 8). The panmixia results suggest a lack 
of compartmentalization across the tissues.
Neighbor-joining trees revealed that proviral 
pol sequences obtained from different anatomical 
compartments intermingled among themselves, con-
sistent with the panmixia results of no divergence, and 
among sequences obtained from plasma at the same time 
points (Fig. 8). The finding that the DNA populations in 
the tissues differed only by the variable frequencies of 
identical sequences, especially for the numbered clones, 
indicates that viral variants and/or infected cells are well 
mixed among all tissues analyzed. The differing frequen-
cies of identical sequences are likely due to varying levels 
of persistence and/or proliferation of infected cells. Clone 
1 remained dominant in the plasma from both treated 
animals, as it was in the virus challenge stock, but it did 
not persist in the untreated animals. Plasma virus col-
lected during ART contained subpopulations that were 
not different from the proviral populations in the tissues 
examined, including the gastrointestinal tract, which has 
been proposed to be a sanctuary site for virus replication 
during ART [32, 51]. This finding suggests that persistent 
viremia during ART is most likely derived from multiple 
anatomic sites.
Analyses of RT‑SHIV intracellular RNA populations 
in tissues of animals treated with ART
To characterize the diversity and divergence of RT-SHIV 
variants expressed in different tissues and to further 
investigate the sources of persistent plasma viremia dur-
ing ART, we sequenced viral intracellular RNA variants 
and compared these populations to those in the plasma 
and to the proviral populations in the tissues of ART-
treated animal 8272 (Fig.  7). The same analysis could 
not be done for animal 8030 due to the low numbers of 
intracellular RNA sequences obtained. Table  1 shows 
the number of RNA sequences obtained from each tis-
sue from both treated macaques. In contrast to the 
untreated macaques, few intracellular RNA sequences 
were detected in animals treated with ART and those 
that were detected contained frame shift mutations or 
large deletions, indicating that they were not replication 
competent. Furthermore, these mutant RNAs did not 
cluster with plasma virus or the proviral DNA detected 
in the tissues. This finding suggests that a minority of the 
infected cells that persist during ART express viral RNA 
and those RNAs that are actively expressed are frequently 
defective (Fig.  7), explaining why only very low levels 
of plasma viremia persist during ART. Most likely, the 
majority of productively expressing RT-SHIV-infected 
cells die within 20 weeks of treatment with combination 
ART, leaving primarily latently infected cells or cells that 
contain defective proviruses. Although all the expressed 
RNA sequences detected in the treated animals were 
defective, no defects were found in the genomes of 
virus that persisted at very low levels in plasma during 
ART in these animals, revealing that some infected cells 
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Fig. 7 Phylogenetic relationships between single-genome proviral sequences obtained from various anatomical compartments after 20 weeks of 
combination ART from animals a 8272 and b 8030. The panmixia probabilities comparing virus populations in the tissues (open colored circles) with 
sequences in the plasma (open black circles) are shown next to each tissue in the key. G to A hypermutants are marked by crosses. Numbers refer to 
clusters of sequences observed more than once here and in previous and subsequent figures. Symbols shown in boxes indicate identical sequences 
that are present on the tree at the location indicated by the pointer. Asterisks indicate bootstrap values >80
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expressing variants that may be replication competent 
also persist during ART but at levels below the detection 
limit of our sampling. Similarly, replication competent 
HIV-1 variants have been reported to persist in HIV-
infected humans treated with ART [52], and are likely to 
be present at some level in most if not all treated patients 
[53]. In addition to the expressed variants being defective, 
we also found that the expressed populations contained 
clusters of identical sequences (Fig.  7). Populations of 
identical intracellular RNA sequences suggest either that 
multiple cells carrying identical variants were expressing 
viral RNA or that single cells (or their descendants) were 
undergoing high levels of viral expression in compari-
son to other infected cells. The finding that the identical 
variants expressed during ART were all defective implies 
that either their expression is from a proliferating cell 
population or from a single cell, but not from local spread 
through viral replication.
Conclusions
The reservoir for HIV-1 during ART must consist of cells 
containing replication competent proviruses that per-
sist and sometimes proliferate despite therapy and result 
in rebound viremia when ART is stopped. The number, 
identity, distribution, and expression levels of these per-
sisting cells are currently unknown. Our findings show 
that the reservoir for RT-SHIV likely includes infected 
cells that are well mixed in different anatomic sites and 
that plasma virus may be derived from multiple tissue 
compartments. These findings are important because 
they imply that exchange of virus and/or infected cells 
between the blood and many tissues is frequent and 
that viral evolution does not likely occur and persist in 
isolation in any specific tissues investigated here, includ-
ing but not limited to PBMC, lymph nodes, gastrointes-
tinal tract, and spleen. Furthermore, the results of this 
study show that genetic analyses on plasma virus appear 
to reflect what is taking place in the tissues in both the 
untreated and treated animals. Consequently, if viral rep-
lication during ART is on-going in the gut, as has been 
proposed, we would expect the newly emergent variants 
to be detectable in the plasma during highly suppres-
sive ART. Such an occurrence was not found here at the 
level of detection provided by single-genome sequencing. 
Lastly, we found RNA expression of defective proviruses 
in both treated and untreated macaques as well as a pos-
sible correlation between the levels proviral expression 
and plasma virus load in the untreated animals. In con-
clusion, these studies strongly suggest that the reservoir 
for RT-SHIVmne during ART is broadly disseminated 
throughout the tissues, that infected cells persisting and/
or proliferating during ART only rarely express viral 
products and, when they do, the genomes are often 
defective, and that the genetics of residual viremia during 
ART reflect the state of expression in the gut and lym-
phoid tissues as well as the blood.
Methods
Virus
RT-SHIVmne is a pathogenic SIV/HIV chimeric virus in 
which SIVmne RT is replaced by HIV-1HxB2 RT [48]. The 
challenge stock was grown in CEMx174 cells and was 
titered on TZM-bl cells. The virus was previously shown 
Fig. 8 Phylogenetic relationships between intracellular RNA and 
DNA single-genome sequences obtained from the same anatomi-
cal compartments after 20 weeks of combination ART from animal 
8272. p values for panmixia are shown where more than 7 sequences 
were obtained for both RNA and DNA. Numbers refer to clusters of 
sequences observed more than once here and in previous and sub-
sequent figures. Symbols shown in boxes indicate identical sequences 
that are present on the tree at the location indicated by the pointer
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to be replication competent and pathogenic in pigtailed 
macaques (Macaca nemestrina) as a useful in vivo model 
to study antiretroviral suppression and emergence of 
drug resistance [47].
Animals
Blood and tissue samples were obtained from pigtailed 
macaques infected for a study previously published [43]. 
Briefly, male pigtailed macaques were infected intrave-
nously with approximately 1  ×  105 infectious units of 
RT-SHIVmne. All animals were housed at the National 
Institutes of Health (NIH) in accordance with the Ameri-
can Association of Accreditation of Laboratory Ani-
mal Care standards and all procedures were performed 
according to protocols approved by the Institutional 
Animal Care and Use Committee of the National Cancer 
Institute. Two animals were left untreated for 30  weeks 
post-infection and two received daily ART beginning at 
10  weeks of infection until necropsy: 20  mg/kg tenofo-
vir and 40  mg/kg emtricitabine were administered sub-
cutaneously and 400 mg EFV was administered orally in 
treats. Blood was drawn weekly or biweekly, from which 
plasma and PBMC were separated. At week 30 post-
infection, animals were euthanized and necropsies were 
performed as previously described [43].
Viral and host cell DNA and RNA isolation 
and measurement in PBMC and tissues
Virus was pelleted from EDTA-anticoagulated plasma 
taken at each time point for each animal and quantita-
tive RT-PCR (qRT-PCR) was performed to determine the 
number SIV RNA (gag) copy equivalents per ml (copy Eq/
ml) of plasma essentially as previously described (Cline 
et al. 2005). The assay limit for quantitation was 30 copy 
Eq/ml of plasma. Total DNA (viral and genomic) was 
extracted from tissues with lysis buffer (Nuclei lysis solu-
tion, Promega, Madison, WI, USA) after extensive wash-
ing using a TissueLyser (Qiagen, Valencia, CA, USA). 
Tissues were processed and nucleic acids extracted as pre-
viously described [43]. Briefly, tissue DNA was extracted 
using the Wizard genomic purification kit (Promega) and 
PBMC DNA was extracted using the Blood DNA kit (Qia-
gen). qPCR (gag) assays were performed as described pre-
viously with a limit of detection of 1 copy/sample [43].
Viral and host cell RNA were extracted from tissues 
stored in RNAlater. Tissues were rinsed with nuclease-
free water and homogenized using a TissueLyser in the 
presence of lysis buffer (RTL, Qiagen) and 20 U of RNase 
inhibitor (Ambion). RNA was extracted from lymphoid 
tissues and lung using the RNeasy kit (Qiagen). As this 
method did not yield good RNA recovery from gastro-
intestinal tract and brain tissues, TRI Reagent (Sigma-
Aldrich, St. Louis, MO, USA) was used to extract RNA 
from brain and gut tissues, as previously described (10) 
[54]. Purified RNA was treated with 10U RNase-free 
DNase I (Roche, Indianapolis, IN, USA) and then precip-
itated and washed again using the RNeasy kit. qRT-PCR 
assays were performed as previously described [43].
Single‑genome sequencing and genetic analyses
SGS of HIV-1 pol was performed as previously described 
[49]. Sequences were aligned using ClustalW. Population 
genetic diversity was calculated as average pairwise dif-
ference (APD) using MEGA4 (http://www.megasoftware.
net) and an in-house program [55]. Shifts in population 
structure were calculated using a subdivision test for 
panmixia with a significance cut off level of p < 10−3 as 
described by the original report to account for the high 
number of comparisons between sequences and nucleo-
tide sites (1, 34, 23). The probability of 10−3 for assigning 
a significant change in viral populations obtained from 
single-genome sequencing was derived statistically tak-
ing into consideration that every nucleotide position is 
compared in every two possible sets of sequences. This 
approach results in more than 1012 comparisons between 
populations of only 10 sequences. Neighbor-joining phy-
logenetic analyses were done using MEGA4. Trees were 
rooted on the subtype B consensus sequence (http://
www.HIV-1.lanl.gov) shown as the lowest (unmarked) 
branch of each tree.
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